Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial
Polyrizon Ltd., a biotech company specializing in intranasal hydrogels, announced the signing of its first U.S. clinical trial agreement to test NASARIX™, its innovative nasal allergy blocker. The multi-center study will evaluate the safety and efficacy of the nasal spray in patients with seasonal allergic rhinitis, marking a crucial step towards c…